Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 251 - 272 av 272 resultater
Tid
Selskap
Tittel
Sektor
Kategori
10 Mar 2022
22:30 CET
CELLECTIS
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
20103010 Biotechnology
-
10 Mar 2022
22:30 CET
CELLECTIS
Monthly information on share capital and company voting rights
20103010 Biotechnology
-
03 Mar 2022
22:45 CET
CELLECTIS
Cellectis publie ses résultats financiers du quatrième trimestre 2021 et de l’exercice 2021
20103010 Biotechnology
-
03 Mar 2022
22:45 CET
CELLECTIS
Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2021 Financial Results
20103010 Biotechnology
-
24 Feb 2022
22:36 CET
CELLECTIS
Cellectis organise une conférence téléphonique pour présenter ses résultats financiers du quatrième trimestre 2021 le vendredi 4 mars 2022 à 14h00 CET
20103010 Biotechnology
-
24 Feb 2022
22:35 CET
CELLECTIS
Cellectis to Hold Fourth Quarter 2021 Earnings Call on Friday March 4, 2022 at 8:00AM EST
20103010 Biotechnology
-
18 Feb 2022
22:40 CET
CELLECTIS
Calyxt annonce le placement d’actions et de bons de souscriptions d’actions pour un montant d’environ 10,9 millions de dollars auprès d’un investisseur institutionnel
20103010 Biotechnology
-
18 Feb 2022
22:40 CET
CELLECTIS
Calyxt Announces Pricing of Offering Of Common Stock and Warrants and Updates Business and Risk Factor Disclosure
20103010 Biotechnology
-
11 Feb 2022
22:30 CET
CELLECTIS
Monthly information on share capital and company voting rights
20103010 Biotechnology
-
11 Feb 2022
22:30 CET
CELLECTIS
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
20103010 Biotechnology
-
10 Feb 2022
22:30 CET
CELLECTIS
Cellectis nomme Bing Wang, PhD, MBA, en tant que directeur financier
20103010 Biotechnology
-
10 Feb 2022
22:30 CET
CELLECTIS
Cellectis Appoints Bing Wang, PhD, MBA as Chief Financial Officer
20103010 Biotechnology
-
11 Jan 2022
22:30 CET
CELLECTIS
Monthly information on share capital and company voting rights
20103010 Biotechnology
-
11 Jan 2022
22:30 CET
CELLECTIS
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
20103010 Biotechnology
-
10 Jan 2022
22:30 CET
CELLECTIS
Cellectis annonce la levée de l’avis de suspension par la FDA des essais cliniques de son partenaire sous licence Allogene Therapeutics
20103010 Biotechnology
-
10 Jan 2022
22:30 CET
CELLECTIS
Cellectis’ Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical Hold on their Clinical Trials
20103010 Biotechnology
-
04 Jan 2022
22:30 CET
CELLECTIS
Cellectis Provides Business Objectives for 2022 and Updates its Corporate Presentation
20103010 Biotechnology
-
04 Jan 2022
22:30 CET
CELLECTIS
Cellectis dévoile ses objectifs business pour l’année 2022 et sa nouvelle présentation corporate
20103010 Biotechnology
-
11 Dec 2021
16:07 CET
CELLECTIS
Cellectis Reports Encouraging Clinical Data from BALLI-01 Study in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, and Preclinical Data from TALGlobin01 at the 63rd American Society of Hematology Annual Meeting
20103010 Biotechnology
-
11 Dec 2021
16:06 CET
CELLECTIS
63e congrès annuel de l’American Society of Hematology : Cellectis annonce des données cliniques encourageantes de l'étude BALLI-01 pour les patients atteints de leucémie aiguë lymphoblastique à cellules B en rechute ou réfractaire, et des don...
20103010 Biotechnology
-
06 Dec 2021
22:30 CET
CELLECTIS
Monthly information on share capital and company voting rights
20103010 Biotechnology
-
06 Dec 2021
22:30 CET
CELLECTIS
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
20103010 Biotechnology
-
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
«
« First
‹
‹‹
4
5
6
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Stock options
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva